B. Mccolgan

1.7k total citations · 2 hit papers
23 papers, 821 citations indexed

About

B. Mccolgan is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, B. Mccolgan has authored 23 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 11 papers in Hepatology and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in B. Mccolgan's work include Liver Disease Diagnosis and Treatment (16 papers), Liver Diseases and Immunity (7 papers) and Liver Disease and Transplantation (5 papers). B. Mccolgan is often cited by papers focused on Liver Disease Diagnosis and Treatment (16 papers), Liver Diseases and Immunity (7 papers) and Liver Disease and Transplantation (5 papers). B. Mccolgan collaborates with scholars based in United States, Spain and Switzerland. B. Mccolgan's co-authors include Robert P. Myers, G. Mani Subramanian, Stephen A. Harrison, Nezam H. Afdhal, Zachary Goodman, Stephen H. Caldwell, Mitchell L. Shiffman, Andrew J. Muir, John G. McHutchison and Catherine Jia and has published in prestigious journals such as Gastroenterology, Hepatology and Journal of Hepatology.

In The Last Decade

B. Mccolgan

23 papers receiving 803 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

2018 257 citations Rohit Loomba, Zeid Kayali et al. Gastroenterology profile →
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

2019 255 citations Arun J. Sanyal, Stephen A. Harrison et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. Mccolgan United States	10	682	422	266	138	135	23	821
Gillian Patman United Kingdom	8	754 1.1×	446 1.1×	274 1.0×	105 0.8×	198 1.5×	43	1.0k
A.-C. Piguet Switzerland	6	853 1.3×	387 0.9×	374 1.4×	88 0.6×	168 1.2×	7	1.0k
Maki Tobari Japan	12	854 1.3×	513 1.2×	287 1.1×	94 0.7×	107 0.8×	31	974
Chuhan Chung United States	12	634 0.9×	404 1.0×	217 0.8×	203 1.5×	124 0.9×	19	814
Sara Badiali Italy	10	499 0.7×	171 0.4×	264 1.0×	137 1.0×	115 0.9×	19	662
Ling Han United States	5	438 0.6×	254 0.6×	163 0.6×	75 0.5×	85 0.6×	6	582
Sarah Temple United States	6	761 1.1×	652 1.5×	144 0.5×	86 0.6×	114 0.8×	16	953
Naoyuki Fujimori Japan	17	620 0.9×	430 1.0×	129 0.5×	164 1.2×	223 1.7×	37	816
Ariel Feldstein United States	2	886 1.3×	538 1.3×	305 1.1×	84 0.6×	124 0.9×	6	989
Abraham Younoszai United States	5	493 0.7×	157 0.4×	216 0.8×	95 0.7×	105 0.8×	6	585

Countries citing papers authored by B. Mccolgan

Since Specialization

Citations

This map shows the geographic impact of B. Mccolgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Mccolgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Mccolgan more than expected).

Fields of papers citing papers by B. Mccolgan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Mccolgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Mccolgan. The network helps show where B. Mccolgan may publish in the future.

Co-authorship network of co-authors of B. Mccolgan

This figure shows the co-authorship network connecting the top 25 collaborators of B. Mccolgan. A scholar is included among the top collaborators of B. Mccolgan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Mccolgan. B. Mccolgan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Danielsson, Tobias, et al.. (2024). Effect of nicotine mouth spray on urges to vape: A randomized, placebo‐controlled, pharmacodynamic clinical trial in exclusive e‐cigarette users. Addiction. 120(1). 95–105. 1 indexed citations

Lawitz, Eric, Edward Gane, Peter Ruane, et al.. (2019). SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis. Journal of Hepatology. 70(1). e794–e794. 9 indexed citations

Sanyal, Arun J., Stephen A. Harrison, Vlad Ratziu, et al.. (2019). The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology. 70(6). 1913–1927. 255 indexed citations breakdown →

Loomba, Rohit, Zeid Kayali, Mazen Noureddin, et al.. (2018). GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 155(5). 1463–1473.e6. 257 indexed citations breakdown →

Younossi, Zobair M., Maria Stepanova, Arun J. Sanyal, et al.. (2018). The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. Journal of Hepatology. 69(6). 1365–1370. 49 indexed citations

Lawitz, Eric, Robert Herring, Ziad Younes, et al.. (2018). Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH. Journal of Hepatology. 68. S57–S57. 9 indexed citations

Lawitz, Eric, Robert Herring, Ziad Younes, et al.. (2018). Su1522 - Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK-1) Inhibitor (Selonsertib) in Combination with an Acetyl-Coa Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH. Gastroenterology. 154(6). S–1166. 3 indexed citations

Harrison, Stephen A., Mazen Noureddin, Robert Herring, et al.. (2018). Su1521 - Preliminary Efficacy and Safety of Acetyl-Coa Carboxylase (ACC) Inhibitor GS-0976 in Patents with Compensated Cirrhosis due to NASH. Gastroenterology. 154(6). S–1166. 1 indexed citations

Muir, Andrew J., Cynthia Levy, Harry L.A. Janssen, et al.. (2018). Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology. 69(2). 684–698. 144 indexed citations

10.

Harrison, S., Mazen Noureddin, Robert Herring, et al.. (2018). Preliminary efficacy and safety of acetyl-CoA carboxylase inhibitor GS-0976 in patients with compensated cirrhosis due to NASH. Journal of Hepatology. 68. S583–S583. 2 indexed citations

11.

Mantry, Parvez, Zeid Kayali, Mazen Noureddin, et al.. (2018). Characterization of changes in lipoprotein profiles of patients with nonalcoholic steatohepatitis treated with the acetyl-CoA carboxylase inhibitor GS-0976. Journal of Hepatology. 68. S583–S584. 1 indexed citations

12.

Ratziu, Vlad, A. Sanyal, Holger Hinrichsen, et al.. (2017). Impact of weight reduction on serum markers and liver histology including progression to cirrhosis in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis. Journal of Hepatology. 66(1). S594–S595. 3 indexed citations

13.

Harrison, S., Vlad Ratziu, Mitchell L. Shiffman, et al.. (2017). Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis. Journal of Hepatology. 66(1). S159–S160. 1 indexed citations

14.

Shea, Patrick R., Gideon M. Hirschfield, M. Shiffman, et al.. (2017). Common variation near glial-derived neurotrophic factor is associated with progression of hepatic collagen content in a genome-wide association study of liver fibrosis phenotypes in patients with primary sclerosing cholangitis. Journal of Hepatology. 66(1). S4–S5. 1 indexed citations

15.

Sanyal, Arun J., Stephen A. Harrison, Vlad Ratziu, et al.. (2017). Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis. Gastroenterology. 152(5). S1055–S1055. 3 indexed citations

16.

Levy, Carlos Emílio, Christopher L. Bowlus, B. Mccolgan, et al.. (2017). Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial. Journal of Hepatology. 66(1). S73–S73. 9 indexed citations

17.

Lawitz, Eric, Fred Poordad, A. Coste, et al.. (2017). Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to suppression of hepatic de novo lipogenesis and significant improvements in MRI-PDFF, MRE, and markers of fibrosis after 12 weeks of therapy in patients with NASH. Journal of Hepatology. 66(1). S34–S34. 22 indexed citations

18.

Kirby, Beth J., et al.. (2017). Pharmacokinetics of selonsertib, GS-9674, and/or GS-0976 in combination in healthy subjects. Journal of Hepatology. 66(1). S151–S152. 5 indexed citations

19.

Levy, Carol J., Bertus Eksteen, M. Shiffman, et al.. (2017). Prospective validation of serum alkaline phosphatase for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis. Journal of Hepatology. 66(1). S360–S361. 2 indexed citations

20.

Mccolgan, B., D. F. Smith, C. Darke, et al.. (2000). Hypothyroidism and Aging: The Rosses' Survey. Thyroid. 10(9). 821–827. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact